11-02/03 :: February / March 2011

nanotimes

Companies Facts

AG. Shares representing 56.1% of the shares of Win- terthur were tendered during the offer period. Toge- ther with shares purchased from shareholders outside of the offer process, the tender offer will result in 3M owning 85.3% of Winterthur’s shares. http://www.leadcheck.com http://investor.3m.com

T

he U.S. Department of Energy (DOE) has awar- ded 3M $4.4 million as part of DOE’s SunShot

Initiative. SunShot aims to reduce the total costs of photovoltaic solar energy systems by about 75%, so that they are cost-competitive with other forms of energy without subsidies. SunShot calls for achieving this goal by the end of the decade. The sum of the 3M award is estimated at $4.4 million over three years. The goal of 3M’s project is to accelerate efforts toward further development and commercialization of 3M™ Ultra Barrier Solar Film. As part of the ini- tiative, 3M will collaborate with DOE’s National Re- newable Energy Laboratory (NREL) located near Den- ver, Colorado, to test the performance and durability of Ultra Barrier Solar Films. NREL recently confirmed moisture vapor transmission rates in the range of 2*10-5

– 8*10-5 g/m2 /day for 3M‘s current Ultra Barri-

er Film 9L product using its electrically based calcium moisture vapor transmission rate (MVTR) test. http://www.3m.com

lithium ion batteries and systems, announced the pricing of an offering of 18,000,000 shares of com- mon stock at a price of $6.00 per share and an offering of $125,000,000 principal amount of con- vertible subordinated notes due 2016. The company has granted the underwriters a 30-day option to

A

123 Systems (NASDAQ:AONE), a developer and manufacturer of advanced Nanophosphate™

purchase up to an additional 2,700,000 shares of common stock, with respect to the stock offering, and up to $18,750,000 aggregate principal amount of the convertible notes, with respect to the converti- ble notes offering. http://www.a123systems.com

a

ap Implantate AG (FSE: AAQ), a German medical technology company, totaled in the first-quarter

of the financial year 2011 sales of EUR6.5 million (previous year: EUR5.8 million), which was a 14% increase on the previous year’s figure. Consolidation of the two German R&D sites in Dieburg and Obern- burg was completed on March 15, 2011. aap plans to publish the full Q1 2011 on May 11, 2011. http://www.aap.de

company, announced at the Molecular Medicine Tri- Conference its entrance in the rapidly growing next generation sequencing (NGS) market with the release of the NGS Collection for Pipeline Pilot. The NGS Collection, together with Accelrys’ industry-leading Pipeline Pilot™ data pipelining software, provide genomics researchers, bioinformaticians, and infor- mation technologists with the tools required to sim- plify NGS application development, to integrate and automate NGS data processing, and to accelerate the analysis and interpretation of the huge volumes of data generated by current DNA sequencing instru- ments.

A

Furthermore, Accelrys announced the new Accelrys Enterprise R&D Architecture, enabling industries and organizations that rely on scientific innovation to bring new products from lab to market more quickly

ccelrys, Inc. (NASDAQ: ACCL), the leading scientific informatics software and services

11